Wednesday, July 8, 2026

Patent intelligence · US

US 12403136

Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof

granted A61KA61K31/05A61K31/055A61K31/352
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 89
Patent details — US 12403136
Jurisdiction
US
Status
granted
Grant date
Sep 2, 2025
Expiration
Aug 28, 2045
Claims
13
CPC classes
A61K, A61K31/05, A61K31/055, A61K31/352
View on Google Patents ↗

Quick answer

US 12403136 (Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
13
CPC classes
A61K, A61K31/05, A61K31/055, A61K31/352, A61K31/353, A61K31/47

More from JAZZ PHARMACEUTICALS RESEARCH UK LIMITED

Related pharmaceutical patents in our USPTO index.

  1. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Sep 25, 2045

    granted
  2. US 12396963

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 21, 2045

    granted
  3. US 12383512

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 7, 2045

    granted
  4. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 7, 2045

    granted
  5. US 12364670

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 17, 2045

    granted
  6. US 12357586

    Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 10, 2045

    granted
  7. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 12403136?

US 12403136 (Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Sep 2, 2025. Expires Aug 28, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12403136?

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.

When does US 12403136 expire?

Our index shows an expiration date of Aug 28, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.